Authors
Latest:
Bispecific Antibodies Generate Excitement in Multiple Myeloma TreatmentMohamad Mohty, MD, PhD, discusses the growing role of bispecific antibodies for the treatment of multiple myeloma.
Latest:
Dr. Mohammad Jahanzeb on Neratinib and Trastuzumab in HER2-Positive Breast CancerMohammad Jahanzeb, MD, medical director, Sylvester Comprehensive Cancer Center at Deerfield Beach, talks about the future of treatment for patients with HER2-positive breast cancer with drugs like neratinib and trastuzumab.
Latest:
Treating Patients With Chemotherapy and BiotherapyMonica Fradkin, RN, BSN, MPH, OCN, Oncology Nursing Education Coordinator, Yale School of Nursing, Smilow Cancer Hospital at Yale-New Haven, discusses treating patients with chemotherapy and biotherapy.
Latest:
Immune Checkpoint Inhibitors in Renal Cell CarcinomaUnspecific immunotherapy with interleukin-2 (IL-2) and interferon-alpha was regarded as the first effective therapy in patients with RCC, leading to remarkable clinical benefit in attaining durable complete responses.
Latest:
Exploring Durvalumab With Radiation Therapy in Patients With Urothelial CarcinomaDuring the 2018 Genitourinary Cancers Symposium, Monika Joshi, MD, assistant professor, Penn State Hershey Medical Center, shared results of a phase Ib study of durvalumab (Imfinzi) and radiation therapy (DUART) followed by adjuvant durvalumab in patients with bladder cancer.
Latest:
Concurrent Durvalumab/RT Plus Adjuvant Durvalumab in Locally Advanced Urothelial Cancer of BladderMonika Joshi, MD, MRCP, associate professor of medicine, Division of Hematology-Oncology, and co-leader for Genitourinary Disease Team, at Penn State Hershey Cancer Institute, discusses the phase Ib/II results of a trial looking at concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with locally advanced urothelial cancer of the bladder.
Latest:
Clinical Findings Identify Associations Between Genomic Correlates and Outcomes in Metastatic CRPCA study aimed at exploring genomic diversity and defining its associations with clinical outcomes in metastatic castration-resistant prostate cancer found that alterations in RB1 were a potent predictor of poor survival and that other common aberrations may serve as prognostic indicators of treatment response, according to recent work published in the Proceedings of the National Academy of Sciences.
Latest:
Treatment of Patients With Waldenstrom's MacroglobulinemiaMorie A. Gertz, MD, chair, Internal Medicine, Mayo Clinic, discusses the treatment options available for patients with Waldenstrom's Macroglobulinemia and the ongoing clinical trials taking place in the field.
Latest:
Conducting a Screening Program in Liver CancerMorris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the process of conducting a screening program for liver cancer.
Latest:
Recent Advances in the Management of Advanced Renal Cell Carcinoma (RCC)In the first article of this series, Moshe Ornstein, MD, a genitourinary medical oncologist at the Cleveland Clinic, gives an overview of renal cell carcinoma and discusses the treatment landscape.
Latest:
The Takeaway Message from the NSABP-47 Trial in HER2-low Breast CancerMothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the NSABP B-47 study, which explored the value of trastuzumab (Herceptin) plus standard adjuvant chemotherapy in breast cancer patients with low levels of HER2 protein.
Latest:
Current and Emerging Immunotherapy Strategies in Advanced Urothelial CancersUntil recently, therapeutic options for the management of advanced urothelial cancers have been limited to traditional cytotoxic agents with modest efficacy. However, the brisk pace of recent discovery in the field of immunotherapy and molecular therapeutics has ushered in a new era for management of patients with urothelial carcinoma.
Latest:
Further Investigation of Veliparib Underway for GlioblastomaMustafa Khasraw, MD, discusses a follow-up trial to the VERTU study for patient with methylated or unmethylated MGMT glioblastoma who responded well to temozolomide chemotherapy and radiation.
Latest:
Comparing Results for 80 mg versus 160 mg Osimertinib in Advanced EGFR+ NSCLCMyung-Ju Ahn, MD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, discusses the findings from the AURA LM study, which compared an 80 mg dose of osimertinib with a 160 mg dose in patients with <em>EGFR</em>-positive advanced non–small cell lung cancer with leptomeningeal metastases.
Latest:
Dr. Housri Discusses theMednetNadine Housri, MD, assistant clinical professor, Yale School of Medicine, discusses theMednet.
Latest:
Prevention and Screening of CRCNadir Arber, MD, MSc, MHA, director of the Integrated Cancer Prevention Center (ICPC), Tel Aviv Sourasky Medical Center, discusses prevention and screening of colorectal cancer (CRC).
Latest:
Activity and Toxicity of Pembrolizumab for NSCLCNaiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).
Latest:
PD-1 and PD-L1 Antibodies in Lung CancerNaiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.
Latest:
DCIS Patients' Risk of Dying From Cardiovascular DiseaseNaomi B. Boekel, MSc, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses DCIS patients' risk of dying from cardiovascular disease.
Latest:
Counting Circulating Tumor CellsNaoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses counting circulating tumor cells for prognostic reasons.
Latest:
Addressing the Role of Consolidation Immunotherapy in Patients With Lung CancerNasser H. Hanna, MD, discusses the key takeaways on the current role of consolidation immunotherapy in patients with lung cancer, which has become standard in this setting. He highlights questions that still need to be addressed in this space.
Latest:
Unmet Needs and Advice for Community Oncologists Treating Patients With NDMMNatalie Callander, MD, offers advice for community oncologists and discusses unmet needs in treating transplant-preferred patients with newly diagnosed MM.
Latest:
CD30-Specific CAR T Cells in Patients With Relapsed/Refractory Hodgkin LymphomaNatalie S. Grover, MD, discusses the potential role of CD30-specific chimeric antigen receptor T cells in patients with relapsed/refractory Hodgkin Lymphoma.
Latest:
Differentiating Pseudoprogression From Hyperprogression in Patients Treated With ImmunotherapiesAdvances in the field have also led to the recognition of other clinical challenges, including unforeseen observations and complications associated with choosing the sequencing of appropriate therapeutic interventions as well as the management of drug-related complications.
